FDA
-
-
-
-
-
-
-
Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold
-
-
-
-
-
-
-
Stifel: 'FULC may be under some pressure'
-
-
-
-
-
-
-
Fulcrum Therapeutics (FULC) PT Raised at Piper Sandler Post Positive 20mg Pociredir Data
-
-
-
-
-
-
-
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
-
-
-
-
-
-
-
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
-
-
-
-
-
-
-
Fulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod
-
-
-
-
-
-
-
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
-
322,967 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

